Table 3.

Bivariate regressions of independent variables with dependent plasma TFV concentrations, HPTN 067 daily dosing arm participants (All Sites; Weeks 18/30 Data Combined; 161 participants, n=302 records), July 2012-May, 2014.

Variable	exp(β) (95% Confidence Interval)	p-value
Age	1.04 (0.99- 1.08)	0.10
Less Than Secondary Education	0.29 (0.14- 0.60)	<0.01
Perceived Problematic Drug Use, Past 3 Months	0.17 (0.05- 0.64)	<0.01
Perceived Problematic Drinking, Past 6 Months	1.36 (−0.64- 3.37)	0.18
Perceived Low Control Over HIV Infection	0.55 (0.28- 1.07)	0.08
Low Perceived External Support for PrEP Scale (Range: 0-2)	0.57 (0.38- 0.85)	<0.01
Participant-Staff Disclosure Challenges Scale (Range 0-4)	0.58 (0.42- 0.78)	<0.01
Staff Judge Patient	2.15 (1.01- 4.40)	0.04
Staff Have Negative Reactions to PrEP Pill Taking	0.34 (0.10- 1.22)	0.10
Low Staff Support for PrEP Pill Taking	1.46 (0.54- 3.99)	0.46
Study-Related Side Effects	2.41 (1.05- 5.53)	0.04
Weight (At weeks 18 and 30; Kg)	0.98 (0.96- 0.99)	0.04
Creatinine Clearance (mL/min)	0.99 (0.97- 1.00)	0.15
Self-report Days Since Last Dose	0.70 (0.62- 0.79)	<0.01
Study Site (ref. Cape Town)
Bangkok	5.12 (2.22- 11.8)	<0.01
Harlem	0.53 (0.23- 1.26)	0.15